Abstract
Osteoarthritis is currently the most commonly known joint condition in dogs. Its challenging classification and pain control have been the focus of studies and drug testing aimed at improving the quality of life for patients. This study aimed to evaluate the use of a canine monoclonal antibody for managing osteoarthritis pain, utilizing the pain guideline-approved scale as an evaluative method answered by the owner. Additionally, we sought to observe the response over one month of treatment. It presents a more practical therapeutic approach, well-received by owners, with fewer side effects compared to the use of anti-inflammatories.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
